> Detailanzeige

Castellanos, Luz E.; Russell, Steven J.; Damiano, Edward R.; Beck, Roy W.; Shah, Viral N.; Bailey, Ryan; Calhoun, Peter; Bird, Keisha; Mauras, Nelly; Wadwa, R. Paul; Forlenza, Greg; Slover, Robert; Messer, Laurel; Cobry, Erin; Shah, Viral; Polsky, Sarit; Jost, Emily; Berget, Cari; Towers, Lindsey; Lange, Samantha; Escobar, Estella; Beatson, Christie; Walker, Sonya; Karami, Angela; [...]

The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes
  • Beteiligte: Castellanos, Luz E.; Russell, Steven J.; Damiano, Edward R.; Beck, Roy W.; Shah, Viral N.; Bailey, Ryan; Calhoun, Peter; Bird, Keisha; Mauras, Nelly; Wadwa, R. Paul; Forlenza, Greg; Slover, Robert; Messer, Laurel; Cobry, Erin; Shah, Viral; Polsky, Sarit; Jost, Emily; Berget, Cari; Towers, Lindsey; Lange, Samantha; Escobar, Estella; Beatson, Christie; Walker, Sonya; Karami, Angela; [...]
  • Erschienen: American Diabetes Association, 2023
  • Erschienen in: Diabetes Care
  • Sprache: Englisch
  • DOI: 10.2337/dc22-1478
  • ISSN: 0149-5992; 1935-5548
  • Schlagwörter: Advanced and Specialized Nursing ; Endocrinology, Diabetes and Metabolism ; Internal Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>We evaluated the performance of the iLet bionic pancreas (BP) in non-Hispanic White individuals (here referred to as “Whites”) and in Black, Hispanic, and other individuals (here collectively referred to as “Minorities”).</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>A multicenter, randomized controlled trial evaluated glycemic management with the BP versus standard of care (SC) in 161 adult and 165 pediatric participants with type 1 diabetes over 13 weeks.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>In Whites (n = 240), the mean baseline-adjusted difference in 13-week HbA1c between the BP and SC groups was −0.45% (95% CI −0.61 to −0.29 [−4.9 mmol/mol; −6.6 to −3.1]; P &amp;lt; 0.001), while this difference among Minorities (n = 84) was −0.53% (−0.83 to −0.24 [−6.0 mmol/mol; −9.2 to −2.8]; P &amp;lt; 0.001). In Whites, the mean baseline-adjusted difference in time in range between the BP and SC groups was 10% (95% CI 7–12; P &amp;lt; 0.001) and in Minorities was 14% (10–18; P &amp;lt; 0.001).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>The BP improves glycemic control in both Whites and Minorities and offers promise in decreasing health care disparities.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang